Eyebright Medical Technology (Beijing) Co., Ltd.

SHSE:688050 Stock Report

Market Cap: CN¥14.0b

Eyebright Medical Technology (Beijing) Future Growth

Future criteria checks 5/6

Eyebright Medical Technology (Beijing) is forecast to grow earnings and revenue by 24.9% and 22.9% per annum respectively. EPS is expected to grow by 24.5% per annum. Return on equity is forecast to be 18.3% in 3 years.

Key information

24.9%

Earnings growth rate

24.49%

EPS growth rate

Medical Equipment earnings growth22.3%
Revenue growth rate22.9%
Future return on equity18.26%
Analyst coverage

Low

Last updated27 May 2025

Recent future growth updates

Eyebright Medical Technology (Beijing) Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 23
Eyebright Medical Technology (Beijing) Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Eyebright Medical Technology (Beijing) Co., Ltd. Just Recorded A 22% Revenue Beat: Here's What Analysts Think

Apr 21
Eyebright Medical Technology (Beijing) Co., Ltd. Just Recorded A 22% Revenue Beat: Here's What Analysts Think

Recent updates

If EPS Growth Is Important To You, Eyebright Medical Technology (Beijing) (SHSE:688050) Presents An Opportunity

Jan 29
If EPS Growth Is Important To You, Eyebright Medical Technology (Beijing) (SHSE:688050) Presents An Opportunity

We Think That There Are Some Issues For Eyebright Medical Technology (Beijing) (SHSE:688050) Beyond Its Promising Earnings

Nov 06
We Think That There Are Some Issues For Eyebright Medical Technology (Beijing) (SHSE:688050) Beyond Its Promising Earnings

Returns At Eyebright Medical Technology (Beijing) (SHSE:688050) Are On The Way Up

Oct 18
Returns At Eyebright Medical Technology (Beijing) (SHSE:688050) Are On The Way Up

Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Oct 01
Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable

Eyebright Medical Technology (Beijing) Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Aug 23
Eyebright Medical Technology (Beijing) Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Returns Are Gaining Momentum At Eyebright Medical Technology (Beijing) (SHSE:688050)

Jul 15
Returns Are Gaining Momentum At Eyebright Medical Technology (Beijing) (SHSE:688050)

Eyebright Medical Technology (Beijing) Co., Ltd.'s (SHSE:688050) 55% Price Boost Is Out Of Tune With Earnings

Jun 10
Eyebright Medical Technology (Beijing) Co., Ltd.'s (SHSE:688050) 55% Price Boost Is Out Of Tune With Earnings

Is Eyebright Medical Technology (Beijing) (SHSE:688050) Using Too Much Debt?

May 13
Is Eyebright Medical Technology (Beijing) (SHSE:688050) Using Too Much Debt?

Eyebright Medical Technology (Beijing)'s (SHSE:688050) Profits May Not Reveal Underlying Issues

Apr 24
Eyebright Medical Technology (Beijing)'s (SHSE:688050) Profits May Not Reveal Underlying Issues

Eyebright Medical Technology (Beijing) Co., Ltd. Just Recorded A 22% Revenue Beat: Here's What Analysts Think

Apr 21
Eyebright Medical Technology (Beijing) Co., Ltd. Just Recorded A 22% Revenue Beat: Here's What Analysts Think

Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Mar 25
Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

A Look At The Fair Value Of Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050)

Mar 18
A Look At The Fair Value Of Eyebright Medical Technology (Beijing) Co., Ltd. (SHSE:688050)

Returns On Capital Are Showing Encouraging Signs At Eyebright Medical Technology (Beijing) (SHSE:688050)

Mar 01
Returns On Capital Are Showing Encouraging Signs At Eyebright Medical Technology (Beijing) (SHSE:688050)

Earnings and Revenue Growth Forecasts

SHSE:688050 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272,754756619N/A4
12/31/20262,283616389N/A5
12/31/20251,787473370N/A4
3/31/20251,457377N/AN/AN/A
12/31/20241,41038818348N/A
9/30/20241,358370-173299N/A
6/30/20241,230349-225255N/A
3/31/20241,072328-208239N/A
12/31/2023951304-158213N/A
9/30/2023806287-79175N/A
6/30/2023713272-76200N/A
3/31/2023638252-25236N/A
12/31/2022579233-21250N/A
9/30/2022549229-51280N/A
6/30/2022500203-58255N/A
3/31/2022480194-71230N/A
12/31/2021433171-92219N/A
9/30/2021416168-10217N/A
6/30/202137615017201N/A
3/31/2021331129-19160N/A
12/31/2020273975123N/A
9/30/202023786-983N/A
6/30/202020468-2343N/A
3/31/202017853-9344N/A
12/31/201919567-9150N/A
12/31/201812720N/A32N/A
12/31/201775-4N/A4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 688050's forecast earnings growth (24.9% per year) is above the savings rate (2.7%).

Earnings vs Market: 688050's earnings (24.9% per year) are forecast to grow faster than the CN market (23.4% per year).

High Growth Earnings: 688050's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 688050's revenue (22.9% per year) is forecast to grow faster than the CN market (12.3% per year).

High Growth Revenue: 688050's revenue (22.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 688050's Return on Equity is forecast to be low in 3 years time (18.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 08:39
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eyebright Medical Technology (Beijing) Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yichi ZhangChina International Capital Corporation Limited
Jin ZhangChina International Capital Corporation Limited
Jiaqi XuCitic Securities Co., Ltd.